Literature DB >> 17283066

An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.

Nicolas Stankovic-Valentin1, Sophie Deltour, Jacob Seeler, Sébastien Pinte, Gérard Vergoten, Cateline Guérardel, Anne Dejean, Dominique Leprince.   

Abstract

Tumor suppressor HIC1 (hypermethylated in cancer 1) is a gene that is essential for mammalian development, epigenetically silenced in many human tumors, and involved in a complex pathway regulating P53 tumor suppression activity. HIC1 encodes a sequence-specific transcriptional repressor containing five Krüppel-like C(2)H(2) zinc fingers and an N-terminal BTB/POZ repression domain. Here, we show that endogenous HIC1 is SUMOylated in vivo on a phylogenetically conserved lysine, K314, located in the central region which is a second repression domain. K314R mutation does not influence HIC1 subnuclear localization but significantly reduces its transcriptional repression potential, as does the mutation of the other conserved residue in the psiKXE consensus, E316A, or the overexpression of the deSUMOylase SSP3/SENP2. Furthermore, HIC1 is acetylated in vitro by P300/CBP. Strikingly, the K314R mutant is less acetylated than wild-type HIC1, suggesting that this lysine is a target for both SUMOylation and acetylation. We further show that HIC1 transcriptional repression activity is positively controlled by two types of deacetylases, SIRT1 and HDAC4, which increase the deacetylation and SUMOylation, respectively, of K314. Knockdown of endogenous SIRT1 by the transfection of short interfering RNA causes a significant loss of HIC1 SUMOylation. Thus, this dual-deacetylase complex induces either a phosphorylation-dependent acetylation-SUMOylation switch through a psiKXEXXSP motif, as previously shown for MEF2, or a phosphorylation-independent switch through a psiKXEP motif, as shown here for HIC1, since P317A mutation severely impairs HIC1 acetylation. Finally, our results demonstrate that HIC1 is a target of the class III deacetylase SIRT1 and identify a new posttranslational modification step in the P53-HIC1-SIRT1 regulatory loop.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283066      PMCID: PMC1899900          DOI: 10.1128/MCB.01098-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

1.  The polycomb protein Pc2 is a SUMO E3.

Authors:  Michael H Kagey; Tiffany A Melhuish; David Wotton
Journal:  Cell       Date:  2003-04-04       Impact factor: 41.582

Review 2.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

3.  SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization.

Authors:  Sarah Ross; Jennifer L Best; Leonard I Zon; Grace Gill
Journal:  Mol Cell       Date:  2002-10       Impact factor: 17.970

4.  Acetylation inactivates the transcriptional repressor BCL6.

Authors:  Oksana R Bereshchenko; Wei Gu; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2002-10-28       Impact factor: 38.330

5.  SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling.

Authors:  Hong-Liang Rui; Ernest Fan; Hai-Meng Zhou; Zhen Xu; Yi Zhang; Sheng-Cai Lin
Journal:  J Biol Chem       Date:  2002-09-09       Impact factor: 5.157

6.  Multiple activities contribute to Pc2 E3 function.

Authors:  Michael H Kagey; Tiffany A Melhuish; Shannon E Powers; David Wotton
Journal:  EMBO J       Date:  2004-12-09       Impact factor: 11.598

7.  SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation.

Authors:  J M Desterro; M S Rodriguez; R T Hay
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

8.  Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.

Authors:  P Dhordain; O Albagli; R J Lin; S Ansieau; S Quief; A Leutz; J P Kerckaert; R M Evans; D Leprince
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

9.  The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo.

Authors:  P Dhordain; O Albagli; S Ansieau; M H Koken; C Deweindt; S Quief; D Lantoine; A Leutz; J P Kerckaert; D Leprince
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

10.  Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors.

Authors:  Wen Yong Chen; Xiaobei Zeng; Mark G Carter; Craig N Morrell; Ray-Whay Chiu Yen; Manel Esteller; D Neil Watkins; James G Herman; Joseph L Mankowski; Stephen B Baylin
Journal:  Nat Genet       Date:  2003-01-21       Impact factor: 38.330

View more
  65 in total

1.  Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells.

Authors:  Capucine Van Rechem; Gaylor Boulay; Sébastien Pinte; Nicolas Stankovic-Valentin; Cateline Guérardel; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

2.  Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice.

Authors:  Ming Hu; Fengming Wang; Xin Li; Christopher Q Rogers; Xiaomei Liang; Brian N Finck; Mayurranjan S Mitra; Ray Zhang; Dave A Mitchell; Min You
Journal:  Hepatology       Date:  2011-12-29       Impact factor: 17.425

3.  SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress.

Authors:  Michael W McBurney; Katherine V Clark-Knowles; Annabelle Z Caron; Douglas A Gray
Journal:  Genes Cancer       Date:  2013-03

4.  SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation.

Authors:  Thang Van Nguyen; Pornpimon Angkasekwinai; Hong Dou; Feng-Ming Lin; Long-Sheng Lu; Jinke Cheng; Y Eugene Chin; Chen Dong; Edward T H Yeh
Journal:  Mol Cell       Date:  2012-01-27       Impact factor: 17.970

5.  Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.

Authors:  Gaylor Boulay; Marion Dubuissez; Capucine Van Rechem; Antoine Forget; Kristian Helin; Olivier Ayrault; Dominique Leprince
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

Review 6.  Metabolism, cytoskeleton and cellular signalling in the grip of protein Nepsilon - and O-acetylation.

Authors:  Xiang-Jiao Yang; Serge Grégoire
Journal:  EMBO Rep       Date:  2007-06       Impact factor: 8.807

Review 7.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

Review 8.  Regulation of transcription factor activity by interconnected post-translational modifications.

Authors:  Theresa M Filtz; Walter K Vogel; Mark Leid
Journal:  Trends Pharmacol Sci       Date:  2013-12-30       Impact factor: 14.819

Review 9.  SUMO: a (oxidative) stressed protein.

Authors:  Marco Feligioni; Robert Nisticò
Journal:  Neuromolecular Med       Date:  2013-09-20       Impact factor: 3.843

10.  A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex.

Authors:  Sean M Armour; Eric J Bennett; Craig R Braun; Xiao-Yong Zhang; Steven B McMahon; Steven P Gygi; J Wade Harper; David A Sinclair
Journal:  Mol Cell Biol       Date:  2013-02-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.